Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658627 | 0.75 | TAF1 (0.48) | BRD4MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL19663742 | 0.71 | CECR2 (0.56) | BRD4MAPT | |
| SCHEMBL17748988 | 0.69 | BRD4 (0.53) | BRD4L3MBTL1MEN1KMT2ALMNA | |
| SCHEMBL24136365 | 0.68 | BRD9 (0.41) | BRD4LMNAMAPT | |
| SCHEMBL926245 | 0.68 | BRD4 (0.74) | BRD4L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL20384320 | 0.66 | BRD4 (0.42) | BRD4MAP2K1MAP2K2 | |
| SCHEMBL9319365 | 0.64 | BRD4 (0.47) | BRD4L3MBTL1MAP2K1MEN1KMT2A | |
| SCHEMBL17748997 | 0.64 | BRD4 (0.57) | BRD4 | |
| SCHEMBL1094507 | 0.63 | CDK2 (0.46) | BRD4L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL29209764 | 0.62 | PRNP (0.45) | BRD4L3MBTL1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | BRD4 1/4885L3MBTL1 3326/4885MAP2K1 2623/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | BRD4 1/4885L3MBTL1 3326/4885MAP2K1 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.